ArticlePurinergic signalling2026
Soluble P2X7 receptor (sP2X7R) as a marker of inflammation in pregnancy.
Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The purinergic P2X7 receptor (P2X7R) is a key regulator of inflammation and pro-inflammatory cytokine release. Recently, a soluble form of P2X7R (sP2X7R) has been identified in the circulation of healthy individuals and significantly increased in patients with inflammatory disorders. As pregnancy is characterized by finely regulated inflammatory adaptations and considered a state of low-grade inflammation, we hypothesized that P2X7R may contribute to the physiological inflammatory status of pregnancy and to pregnancy-related inflammatory disorders. A cohort of 90 pregnant women was evaluated at the first, second, and third trimester of pregnancy, and 30 age-matched non-pregnant women were used as controls. We measured sP2X7R blood concentrations, and the neutrophil-to-lymphocyte ratio (NLR) was used as a reference inflammatory marker. Associations with maternal characteristics, pregnancy complications and foetal sex were investigated. Serum sP2X7R concentrations were significantly higher in pregnant than in control women and increased progressively throughout pregnancy. Although sP2X7R and NLR showed similar trends, sP2X7R provided complementary information. First-trimester sP2X7R concentrations were significantly higher in multigravida women, in those with gestational hypothyroidism, and in those carrying a male foetus. No significant differences were observed according to Body Mass Index (BMI), gestational diabetes, or gestational hypertension. Furthermore, sP2X7R was detectable in umbilical cord blood and positively correlated with maternal circulating concentrations. To our knowledge, this is the first study to show that circulating sP2X7R increases during normal pregnancy and reflects the physiological inflammatory adaptations of gestation. The results indicate that circulating sP2X7R is a potential biomarker of inflammatory responses and maternal-fetal immune interactions during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.